Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Care teams have access to AI-enabled tools like summarization to spend less time on paperwork
whether youre managing fatigue, hormone imbalance, inflammation, or age-related concerns
Due to these findings, oral Wegovy would currently be my preferred choice when cardiovascular risk reduction is top priority, says Anton, noting that both medications seem promising for people focused primarily on blood glucose control or creating modest improvements in blood pressure and cholesterol
Learn more about all things Functional Medicine, and Neurocognitive Peptides on The Better Yoo Podcast
Higher dose exploration (4.5mg trials) Rationale for testing 4.5mg: Investigate maximum tolerable dose Determine if higher = better weight loss Establish safety ceiling Results at 4.5mg weekly: Weight loss: ~12% (vs 10% at 2.4mg) Incremental benefit: Only 2% additional loss Side effects: Significantly worse nausea/vomiting Dropout rate: Higher than 2.4mg Clinical verdict: 4.5mg not recommended for routine use Risk-benefit ratio unfavorable 2.4mg remains optimal Some individuals may tolerate 3.0mg as compromise CagriSema combination dosing trials REDEFINE-1 protocol: Semaglutide: 2.4mg weekly (standard titration over 16 weeks) Cagrilintide: 2.4mg weekly (12-week titration) Both given as separate injections Started simultaneously from week 1 Semaglutide escalation (standard): Weeks 1-4: 0.25mg Weeks 5-8: 0.5mg Weeks 9-12: 1.0mg Weeks 13-16: 1.7mg Week 17+: 2.4mg Cagrilintide escalation (when combined): Weeks 1-4: 0.6mg Weeks 5-8: 1.2mg Weeks 9-12: 1.8mg Week 13+: 2.4mg Results: 15.6% average weight loss (68 weeks) Superior to either alone Side effects manageable with slow titration Combination well-tolerated See our cagrilintide and semaglutide combination guide and semaglutide dosage calculator
Hydration Proper hydration supports skin elasticity and function
US$ 27.78
US$ 26.37
US$ 28.86
US$ 23.86
US$ 21.17
US$ 24.17
